The newly founded APTA Therapeutics has acquired assets from Berlin Cures and intends to continue clinical development of rovunaptabin, formally BC 007.
APTA Therapeutics is a clinical stage biopharmaceutical company focused on the development of innovative therapies that target regulatory autoantibody associated diseases.
Dr. Oliver von Stein, Chief Executive Officer of APTA Therapeutics, commented:
“We firmly believe in the therapeutic potential of rovunaptabin and post hoc analyses of the phase 2 study data (BLOC) are ongoing. Our priority is to support additional clinical studies with rovunaptabin in post viral infectious diseases in collaboration with renowned national and international medical institutes to set the foundation for a registration study necessary for market approval.”